Biotech Values

[DewDiligence]

Yet another case of a survival benefit without a time-to-progression benefit:

http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh45859_2005-01-11_12-18-10_wen...

>>
Dendreon cancer drug fails to meet main trial goal

NEW YORK, Jan 11 (Reuters) - Dendreon Corp. (DNDN.O: Quote, Profile, Research) said on Tuesday a late-stage study of its experimental prostate cancer drug did not slow the disease's progression, but an analysis of overall survival in the target audience for the treatment showed a survival benefit compared with placebo.

The Phase III trial of the drug, Provenge, showed the survival rates and the median survival benefit compared with placebo were similar to results observed in a three-year survival analysis of an earlier trial. The final results of that trial will be presented at a conference in February.
<<